Drug treatment for vertigo;Medikamentöse schwindeltherapie

Laryngo- Rhino- Otologie

Volumn 82, Issue 1, 2003, Pages 44-61

  Schmal F ^a   Stoll, W ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Dizziness; Therapy of motion sickness; Therapy of vertigo

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIHISTAMINIC AGENT; ANTIVERTIGO AGENT; BENZODIAZEPINE; BETAHISTINE; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; CLONAZEPAM; CORTICOSTEROID; DIAZEPAM; DIMENHYDRINATE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; EPHEDRINE; FLUNARIZINE; GRANISETRON; HALOPERIDOL; LORAZEPAM; MECLOZINE; NEUROLEPTIC AGENT; ONDANSETRON; PERPHENAZINE; SEROTONIN 3 ANTAGONIST; SULPIRIDE; THIETHYLPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG;

ANTICHOLINERGIC EFFECT; CHRONIC DISEASE; CONSTIPATION; CONTINUING EDUCATION; CORTICOSTEROID THERAPY; DEPRESSION; DRUG CONTRAINDICATION; DRUG MECHANISM; HOMEOPATHY; HUMAN; INNER EAR DISEASE; MENIERE DISEASE; MOTION SICKNESS; MUSCLE RELAXATION; MYDRIASIS; PARKINSONISM; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TACHYCARDIA; VERTIGO;

ANTIEMETICS; CENTRAL NERVOUS SYSTEM AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MENIERE'S DISEASE; VERTIGO;

EID: 0142079051     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36903     Document Type: Review

References (70)

1. Fleck C. Die Schwindeltablette - nur ein Tablettenschwindel? Z Arztl Fortbild Qualitätssich 2000; 94: 501-507
2. Brandt T. Vertigo. Its Multisensory Syndroms, 2. Auflage ed. Berlin, Heidelberg, New York: Springer Verlag, 1999.
3. Schmäl F, Stoll W. Kinetosen. HNO 2000; 48: 346-356
4. Rascol O, Hain TC, Brefel C, Benazet M, Clanet M, Montastruc JL. Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs 1995; 50: 777-791
5. Smith PF, Darlington CL. Recent advances in the pharmacology of the vestibulo-ocular reflex system. Trends Pharmacol Sci 1996; 17: 421-427
6. Waldfahrer F, Finke C, Iro H. Aktuelle Aspekte der medikamentösen Schwindeltherapie. In: Stoll W, ed. Vestibuläre Erkrankungen. Stuttgart, New York: Thieme Verlag, 2001: 98-107
7. Thai-Van H, Bounaix MJ, Fraysse B. Menière's disease: pathophysiology and treatment. Drugs 2001; 61: 1089-1102
8. Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 2001; 15: 853-870
9. Botta L, Mira E, Valli S et al. Effects of betahistine and of its metabolites on vestibular sensory organs. Acta Otorhinolaryngol Ital 2001; 21: 24-30
10. Krishna BA, Kirtane MV, Sangeeta T, Gopinath G. Pre and post betahistine therapy 99 m Tc-HMPAO brain spect studies in patients with vertigo. Neurol India 2000; 48: 255-259
11. Laurikainen E, Miller JM, Nuttall AL, Quirk WS. The vascular mechanism of action of betahistine in the inner ear of the guinea pig. Eur Arch Otorhinolaryngol 1998; 255: 119-123
12. Baloh R. Approach to the dizzy patient. In: Baloh R (ed). Bailliere's Clinical Neurology. Cambridge: Cambridge University Press, 1994: 435-463
13. Hutchinson MA, Smith PF, Darlington CL. Tolerance to the ataxic effects of diazepam in guinea pig is not associated with a reduced sensitivity of GABAA receptors in the vestibular nucleus. Eur J Pharmacol 1996; 301: 83-90
14. Gilchrist DP, Darlington CL, Smith PF. Effects of flunarizine on ocular motor and postural compensation following peripheral vestibular deafferentation in the guinea pig. Pharmacol Biochem Behav 1993; 44: 99-105
15. Lucot JB. Pharmacology of motion sickness. J Vestib Res 1998; 8: 61-66
16. Ariyasu L, Byl FM, Sprague MS, Adour KK. The beneficial effect of methylprednisolone in acute vestibular vertigo. Arch Otolaryngol Head Neck Surg 1990; 116: 700-703
17. Yamanaka T, Sasa M, Amano T, Miyahara H, Matsunaga T. Role of glucocorticoid in vestibular compensation in relation to activation of vestibular nucleus neurons. Acta Otolaryngol (Stockh.) Suppl 1995; 519: 168-172
18. Jerram AH, Darlington CL, Smith PF. Methylprednisolone reduces spontaneous nystagmus following unilateral labyrinthectomy in guinea pig. Eur J Pharmacol 1995; 275: 291-293
19. Alice C, Paul AE, Sansom AJ, Maclennan K, Darlington CL, Smith PF. The effects of steroids on vestibular compensation and vestibular nucleus neuronal activity in the guinea pig. J Vestib Res 1998; 8: 201-207
20. Rice GP, Lesaux J, Vandervoort P, Macewan L, Ebers GC. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997; 62: 282-284
21. Vibert N, Vidal PP. In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur J Neurosci 2001; 13: 735-748
22. Schlatter M, Kerr DR, Smith PF, Darlington CL. Evidence that the gingko biloba extract, EGb 761, neither accelerates nor enhances the rapid compensation of the static symptoms of unilateral vestibular deafferentation in guinea pig. J Vestib Res 1999; 9: 111-118
23. Stoll W, Matz D, Most E, Rudolf G. Schwindel und Gleichgewichtsstörungen, 3. Auflage ed. Stuttgart, New York: Thieme Verlag, 1998
24. Ussmuller J, Sanchez-Hanke M, Leuwer R, Klinische Relevanz entwicklungsbedingter Veränderungen des Saccus, Laryngo-Rhino-Otol 2001; 80: 308-312
25. Claes J, Van de Heyning PH. A review of medical treatment for Menière's disease. Acta Otolaryngol (Stockh.) Suppl 2000; 544; 34-9.: 34-39
26. Petermann W, Mulch G. Langzeittherapie des M. Menière. Betahistin-dihydrochlorid und Hydrochlorothiazid im Wirkungsvergleich, Fortschr Med 1982; 100: 431-435
27. Fraysse B, Bebear JP, Dubreuil C, Berges C, Dauman R. Betahistine dihydrochloride versus flunarizine. A double-blind study on recurrent vertigo with or without cochlear syndrome typical of Menière's disease. Acta Otolaryngol (Stockh,) Suppl 1991; 490: 1-10
28. Meyer ED. Zur Behandlung des Morbus Menière mit Betahistindisemilat (Aequamen), Doppelblindstudie gegen Plazebo (crossover). Laryngo-Rhino-Otol 1985; 64: 269-272
29. Oosterveld WJ. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. J Laryngol Otol 1984; 98: 37-41
30. James AL, Burton MJ. Betahistine for Menière's disease or syndrome. Cochrane Database Syst Rev 2001; CD001873
31. Larsen HC, Angelborg C, Hultcrantz E. Cochlear blood flow related to hyperosmotic solution. Arch Otorhinolaryngol 1982; 234: 145-150
32. Larsen HC, Angelborg C. Effect of galactose and isosorbide on cochlear blood flow. ORLJ Otorhinolaryngol Relat Spec 1987; 49: 99-102
33. Horner KC, Aurousseau C, Erre JP, Cazals Y. Long-term treatment with chlorthalidone reduces experimental hydrops but does not prevent the hearing loss. Acta Otolaryngol (Stockh.) 1989; 108: 175-183
34. Prazma J. Effect of glycerol on cochlea microcirculation. Acta Otolaryngol (Stockh.) 1981; 92: 459-461
35. Magliulo G, Della RC, Ungari C, Muscatello M. The effect of glycerol on short-term experimental endolymphatic hydrops. J Otolaryngol 1991; 20: 188-192
36. Magliulo G, Vingolo GM, Petti R, Cristofari P. Experimental endolymphatic hydrops and glycerol. Electrophysiologic study. Ann Otol Rhinol Laryngol 1993; 102: 596-599
37. Magliulo G, Ungari C, Della RC, Muscatello M, Vingolo GM. The effect of glycerol on the guineapig hydropic ear. Clin Otolaryngol 1991; 16: 483-487
38. Shinkawa H, Kimura RS. Effect of diuretics on endolymphatic hydrops. Acta Otolaryngol (Stockh.) 1986; 101: 43-52
39. van Deelen GW, Huizing EH. Use of a diuretic (Dyazide) in the treatment of Menière's disease. A double-blind cross-over placebo-controlled study. ORLJ Otorhinolaryngol Relat Spec 1986; 48: 287-292
40. Klockhoff I, Lindblom U. Menière's disease and hydrochlorothiazide (Dichlotride) - a critical analysis of symptoms and therapeutic effects. Acta Otolaryngol (Stockh.) 1967; 63: 347-365
41. Klockhoff I, Lindblom U, Stahle J. Diuretic treatment of Menière disease. Long-term results with chlorthalidone. Arch Otolaryngol 1974; 100: 262-265
42. Tomoda K, Suzuka Y, Iwai H, Yamashita T, Kumazawa T. Menière's disease and autoimmunity: clinical study and survey. Acta Otolaryngol (Stockh.) Suppl 1993; 500: 31-34
43. Blakley BW. Clinical forum: a review of intratympanic therapy. Am J Otol 1997; 18: 520-526
44. Barrs DM, Keyser JS, Stallworth C, McElveen JT, Jr. Intratympanic steroid injections for intractable Menière's disease. Laryngoscope 2001; 111: 2100-2104
45. Silverstein H, Isaacson JE, Olds MJ, Rowan PT, Rosenberg S. Dexamethasone inner ear perfusion for the treatment of Menière's disease: a prospective, randomized, double-blind, crossover trial. Am J Otol 1998; 19: 196-201
46. Rarey KE, Curtis LM, ten Cate WJ. Tissue specific levels of glucocorticoid receptor within the rat inner ear. Hear Res 1993; 64: 205-210
47. Haid T. Evaluation of flunarizine in patients with Menière's disease. Subjective and vestibular findings. Acta Otolaryngol (Stockh.) Suppl 1988; 460: 149-153
48. Angelborg C. Pharmacological treatment of Menière's disease. A review of common remedies with special emphasis on vasodilators, including hyperosmolar substances and hearing. Scand Audiol Suppl 1986; 26: 33-36
49. Langman AW, Kemink JL, Graham MD. Titration streptomycin therapy for bilateral Menière's disease. Follow-up report. Ann Otol Rhinol Laryngol 1990; 99: 923-926
50. Morgenstern C, Ninoyu O, Mori N, Mertens HP. Effect of aminoglycosides on experimentally induced endolymphatic hydrops. Laryngo-Rhino-Otol 1986; 65: 371-373
51. Pender DJ. Gentamicin tympanoclysis: effects on the vestibular secretory cells. Am J Otolaryngol 1985; 6: 358-367
52. Hirsch BE, Kamerer DB. Role of chemical labyrinthectomy in the treatment of Menière's disease. Otolaryngol Clin North Am 1997; 30: 1039-1049
53. Harrier SG, Kasperbauer JL, Facer GW, Beatty CW. Transtympanic gentamicin for Menière's syndrome. Laryngoscope 1998; 108: 1446-1449
54. Magnusson M, Padoan S. Delayed onset of ototoxic effects of gentamicin in treatment of Menière's disease. Rationale for extremely low dose therapy. Acta Otolaryngol (Stockh.) 1991; 111: 671-676
55. Shea JJ, Ge X. Factors influencing results with streptomycin perfusion of the labyrinth. Am J Otol 1993; 14: 570-575
56. Nedzelski JM, Chiong CM, Fradet G, Schessel DA, Bryce GE, Pfleiderer AG. Intratympanic gentamicin instillation as treatment of unilateral Menière's disease: update of an ongoing study. Am J Otol 1993; 14: 278-282
57. Kimura RS, Lee KS, Nye CL, Trehey JA. Effects of systemic and lateral semicircular canal administration of aminoglycosides on normal and hydropic inner ears. Acta Otolaryngol (Stockh.) 1991; 111: 1021-1030
58. Pyykko I, Ishizaki H, Kaasinen S, Aalto H. Intratympanic gentamicin in bilateral Menière's disease. Otolaryngol Head Neck Surg 1994; 110: 162-167
59. Murray JB. Psychophysiological aspects of motion sickness. Percept Mot Skills 1997; 85: 1163-1167
60. Ruckenstein MJ, Harrison RV. Motion sickness. Helping patients tolerate the ups and downs. Postgrad Med 1991; 89: 139-144
61. Gay L, Carliner P. The prevention and treatment of motion sickness. Science 1949: 109: 359
62. Wood CD, Kennedy RE, Graybiel A, Trumbull R, Wherry RJ. Clinical effectiveness of anti-motion-sickness drugs. Computer review of the literature. JAMA 1966; 198: 1155-1158
63. Weinstein SE, Stern RM. Comparison of marezine and dramamine in preventing symptoms of motion sickness. Aviat Space Environ Med 1997; 68: 890-894
64. Ramanathan R, Geary RS, Bourne DW, Putcha L. Bioavailability of intranasal promethazine dosage forms in dogs. Pharmacol Res 1998; 38: 35-39
65. Oman CM. Spacelab experiments on space motion sickness. Acta Astronaut 1987; 15: 55-66
66. Mowrey DB, Clayson DE. Motion sickness, ginger, and psychophysics. Lancet 1982; 20: 1: 655-657
67. Grontved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol (Stockh.) 1988; 105: 45-49
68. Holtmann S, Clarke AH, Scherer H, Hohn M. The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. Acta Otolaryngol (Stockh.) 1989; 108: 168-174
69. Stoll W. Otogener Schwindel, Differenzierung und Therapie. Laryngo-Rhino-Otol 1993; 72: 311-315
70. Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol 2001; 22: 619-624